Reassessing the PFO-Migraine Trials: Are We Closer to Closure?
- PMID: 33573736
- DOI: 10.1016/j.jacc.2020.12.017
Reassessing the PFO-Migraine Trials: Are We Closer to Closure?
Keywords: PFO occluder; PREMIUM trial; PRIMA trial; migraine headache with aura; patent foramen ovale.
Conflict of interest statement
Funding Support and Author Disclosures Dr. Ahmed has received consulting fees from Eli Lilly, Amgen, AbbVie, and ElectroCore; has served on advisory boards for Amgen and Supernus; has served as a speaker for AbbVie; and has received funding for an investigator-initiated trial from Teva and Eli Lilly. Dr. Sommer has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Pooled Analysis of PFO Occluder Device Trials in Patients With PFO and Migraine.J Am Coll Cardiol. 2021 Feb 16;77(6):667-676. doi: 10.1016/j.jacc.2020.11.068. J Am Coll Cardiol. 2021. PMID: 33573735
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous